Novel CXCR2 selective antagonist with a low CXCR1 antagonism preference

Novel potent CXCR2 antagonist

Nonsteroidal dermatologic and anti-inflammatory agent, blocking the MEK1/2-Erk1/2 pathway, inhibiting chronic contact hypersensitivity responses (CHRs) and the rebound phenomenon following withdrawal of corticosteroid therapy without immunosuppression

Novel inhibitor of CXCL8-mediated chemotaxis through selective regulation of CXCR2-mediated signaling

Novel low-impact ampakine that can safely activate AMPA receptors without causing excito-neurotoxicity, rapidly crossing the blood-brain barrier (T max = 2 min), protecting against respiratory depression

Potent LTB4 receptor antagonist

Novel potent and substrate-competitive PTP1B and TCPTP dual inhibitor

Novel Wnt/β-Catenin Inhibitor, Preferentially Inhibiting the Growth of Breast Cancer Stem-like Cells

Potent antimalarial agent against Plasmodium falciparum 3D7

Potent antimalarial agent against Plasmodium falciparum 3D7

Novel orally efficacious antimalarial agent against P. falciparum 3D7 ( IC50: 51 nM)

Potent serine protease inhibitor, targeting the S 2 S 3 thrombin and FXa subsites

Direct thrombin inhibitor, preventing occlusive arterial and venous thrombosis in a canine model of vascular injury

Novel potent and selective inhibitor of PI5P4Ks

Inhibitor of PIM, suppressing cyclin-Dependent Kinase 2 (CDK2)

Novel potent pregnane X Receptor (PXR) agonist

Novel dual PXR and AhR agonist

Potent anti-cancer agent

Inducer of demyelination and motor dysfunction via upregulation of IGF-1

Agonist for the cannabinoid receptors, with Ki values of 59.21 nM at CB1 and 136.38 nM at CB2 and EC50 values of 11.98 nM at CB1 and 16.2 nM at CB2

5-HT1A receptor agonist

Novel r(CUG) repeat expansion cleaver, specifically recognizing the 3-dimensional structure of r(CUG)exp, cleaving it more selectively among transcripts containing short, nonpathogenic r(CUG) repeats than an oligonucleotide that recognizes RNA sequence vi

Novel fluorescent RXR agonist

Novel Serotonin 5-HT 2C Receptor Positive Allosteric Modulator (PAM) with Enhanced Drug-like Properties

Inhibitor of prostate-specific membrane antigen (PSMA)

Novel anticancer agent, effectively killing multi-drug resistant cancer cells and a panel of different cancer cells originated from a variety of different tissues including breast and skin, preventing tubulin polymerization, leading to the cell cycle arre

Novel anticancer agent, effectively killing multi-drug resistant cancer cells and a panel of different cancer cells originated from a variety of different tissues including breast and skin, preventing tubulin polymerization, leading to the cell cycle arre

Novel cell permeable degrader of BRD4

Novel potent dual inhibitor of ALK and c-Met

Dual inhibitor of angiogenesis and lysophosphatidic acid acyltransferase